No Detail Found!

Diagnostic Accuracy of Risk of Ovarian Malignancy Algorithm (ROMA) in Post-menopausal Patients with Ovarian Mass.

Author(s)
Erum Salim Department of Chemical Pathology, Dr. Ziauddin University Hospital, Karachi, Pakistan
Adnan Mustafa Zubairi Department of Chemical Pathology, Dr. Ziauddin University Hospital, Karachi, Pakistan
Syed Hasan Danish Department of Community Health Sciences, Dr. Ziauddin University Hospital, Karachi, Pakistan
Usman Ali Department of Chemical Pathology, Dr. Ziauddin University Hospital, Karachi, Pakistan
Abstract
Objective: To determine the diagnostic accuracy of ROMA in postmenopausal women with history of ovarian mass. Study Design: Observational study. Place and Duration of Study: Dr. Ziauddin University Hospital, Karachi, from May 2014 to June 2015. Methodology: Two hundred and sixty postmenopausal women of 40-65 years of age with ovarian masses, planned for surgery, were included in the study. Their samples were obtained preoperatively and analysed on Abbot Architect i1000 SR immunoassay analyser for quantitative estimation of tumor markers, i.e. HE4 and CA125. By combination of these two tumor markers, ROMA scores were calculated and studied after histopathological verification of masses. Results: Total number of patients were 260, out of which 122 (46.9%) were diagnosed as having ovarian cancer, while 138 (53.0%) were diagnosed as benign condition. Median ROMA score levels in patients with malignant masses were 95.58 (IQR=44.4) as compared to 20.6 (IQR=14) in benign masses. ROMA had sensitivity 92.6% (CI=86.47-96.04), specificity 78.3% (CI=70.09-83.82), positive predictive value 79% (CI=70.87-84.29), negative predictive value 92.3% (CI=86.02-95.9) and positive likelihood ratio 4.26, while negative likelihood ratio 0.1. Diagnostic accuracy of ROMA was 85%, based on ROC curve analysis. ROMA had the highest sensitivity in detecting ovarian carcinoma. Conclusion: ROMA is a very useful diagnostic tool for the preoperative stratification of patients with ovarian masses showing 85% diagnostic accuracy. However, there is need of more studies with homogenous laboratory procedures for HE4 and CA125 assays as well as patients, selection criteria, so we can draw firm conclusion about utility of ROMA in clinical setups.
Publication Details
Page(s) 440-444
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 6, Year: 2018

Request the full text from PASTIC

References
SharmaI,SarmaU,DuttaUC, 2014.Pathology of ovarian tumour - A hospital-based study,Int J Medi Sci Clin Invent (IJMSCI) 1 284 -6
AntonC,CarvalhoFM,OliveiraEI,MacielGA,BaracatEC,CarvalhoJP, 2012.A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses,Clinics (Sao Paulo) 67 437 -41
ChoKR,ShihIM. Ovarian,Cancer, 2009.,Annu Rev Pathol 4 287 -313
GropTV,CadronI,DesspierreE,DaemenA,LuenenK,AmanatF, 2011.HE4 and CA125 as a diagnostic test in ovarian cancer prospective validation of the risk of ovarian malignancy algorithm,Br J Cancer 104 863 -70
ThanapprapasrD,Wilailak S, 2012.Screening for ovarian cancer in women, ovarian cancer clinical and therapeutic perspectives, 43 -54
SarojiniS,TamirA,LimH,LiS,ZhangS,GoyA, 2012.Early detection biomarkers for ovarian cancer,J Oncol 1 -15
MooreRG,MillerMC,DiselvestroP,LandrumLM,GanjewskiW,BallJJ, 2011.Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass,Obstet Gynecol 118 280 -8
MontagnanaM,DaneseE,RuzzenenteO,BrescianiV,NuzzoT,GelatiM., 2011.The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?,Clin Chem Lab Med 49 521 -5
KobayashiE,UedaY,MatsuzakiS,YokoyamaT,KimuraT,YoshinoK, .Biomarkers for screening, diagnosis, and monitoring of ovarian cancer [internet],2012 September 7 -
BandieraE,RomaniC,SpecchiaC,ZanottiL,GalliC,RuggeriG, 2011.Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management,Cancer Epidemiol Biomarkers Prev 20 2496 -506
SchimnichAA, 2013.A Review of current serum markers and their clinical applications, -
BastRC,SkatesS,LokshinA,MooreRG, 2012.Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers,Int J Gynecol Cancer 22 S5 -8
MooreRG,Jabre-RaughleyM,BrownAK, 2010.Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass,Am J Obstet Gynecol 203 228 -
KadijaS,StefanovicA,JeremicK., 2012.The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis,Int J Gynecol Cancer 22 238 -44
KarlsenMA,SandhuN,HøgdallC, 2012.Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass,Gynecol Oncol 127 379 -83
MooreRG,HawkinsDM,MillerMC,LandrumLM,GajewskiW,BallJJ, 2014.Combining clinical assessment and the risk of ovarian malignancy algorithm for the prediction of ovarian cancer,Gynecol Oncol 135 547 -51
RuggeriG,BandieraE,ZanottiL. HE4, 2011.and epithelial ovarian cancer: Comparison and clinical evaluation of two immunoassays and a combination algorithm,Clinica Chimica Acta 412 1447 -53
HellströmI,RaycraftJ,Hayden-LedbetterM,LedbetterJA,SchummerM,McIntoshM, 2003.The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma,Cancer Res 63 3695 -700
Van GorpT,VeldmanJ,Van CalsterB,CadronI,LeunenK,AmantF, 2012.Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses,Eur J Cancer 48 1649 -56
Al MusalhiK,Al KindiM,Al AisaryF,RamadhanF,Al RawahiT,Al HataliK, 2016.Risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in the preoperative assessment of patients with adnexal mass,Oman Med J 31 336 -44
SimmonsAR,BaggerlyK,BastRC, 2013.The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas,Oncology 27 548 -56
0

Citations

0

Downloads

117

Views